Company Filing History:
Years Active: 2005-2007
Title: Rachel Ferri: Innovator in JNK Inhibition
Introduction
Rachel Ferri is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that act as selective inhibitors of JNK (c-Jun N-terminal kinase). With a total of 4 patents to her name, Ferri's work is paving the way for new treatments for various diseases.
Latest Patents
Ferri's latest patents focus on methods of using indazole derivatives as JNK inhibitors. One of her notable inventions discloses compounds that have activity as selective inhibitors of JNK. These indazole derivatives are designed to treat a wide range of conditions that respond to JNK inhibition. Additionally, she has developed pharmaceutical compositions containing these compounds, which are aimed at treating inflammatory diseases and disorders.
Career Highlights
Rachel Ferri is currently associated with Signal Pharmaceuticals, Inc., where she continues her innovative work in drug development. Her research has been instrumental in advancing the understanding of JNK inhibition and its therapeutic applications.
Collaborations
Ferri has collaborated with esteemed colleagues such as Shripad S Bhagwat and Yoshitaka Satoh, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Rachel Ferri's contributions to the field of pharmaceutical sciences, particularly through her patents on JNK inhibitors, highlight her role as a leading inventor. Her work not only advances scientific knowledge but also holds promise for the treatment of various diseases.